The risk of chronic kidney disease in relation to anthropometric measures of obesity: A Swedish cohort study

Ensieh Memarian¹*, Peter M. Nilsson¹, Isac Zia¹, Anders Christensson² and Gunnar Engström¹

Abstract

Background: It has been shown that individuals with obesity have a higher risk for chronic kidney disease (CKD). However, it is unclear which measure of obesity is most useful for prediction of CKD in the general population. The aim of this large prospective study was to explore the association between several anthropometric measures of obesity, i.e., body mass index (BMI), waist circumference (WC), waist circumference to height ratio (WHtR), waist-to-hip ratio (WHR), percentage of body fat (BF%), weight, height and incidence of hospitalizations due to CKD, in a population-based cohort study.

Methods: The ‘Malmö Diet and Cancer Study (MDCS)’ cohort in Sweden was examined during 1991 to 1996. A total of 28,449 subjects underwent measurement of anthropometric measures and blood pressure and filled out a questionnaire. Incidence of in- and outpatient hospital visits for CKD was monitored from the baseline examination over a mean follow-up of 18 years. Cox proportional hazards regression was used to explore the association between anthropometric measures and incidence of CKD, with adjustments for risk factors.

Results: The final study population included 26,723 subjects, 45-73 years old at baseline. Higher values of BMI, WC, WHR, WHtR and weight were associated with an increased risk of developing CKD in both men and women. Only in women, higher values of BF% was associated with higher risk of CKD. Comparing the 4th vs 1st quartile of the obesity measure, the highest hazard ratio (HR) for CKD in men was observed for BMI, HR 1.51 (95% CI: 1.18-1.94) and weight (HR 1.52 (95% CI: 1.19-1.94). For women the highest HR for CKD was observed for BF%, HR 2.01 (95% CI: 1.45-2.78).

Conclusions: In this large prospective study, all anthropometric measures of obesity were associated with a substantially increased incidence of CKD, except for BF% in men. Some measures were slightly more predictive for the risk of CKD than others such as BMI and weight in men and BF% in women. In clinical daily practice use of all anthropometric measures of obesity might be equally useful to assess the risk of developing CKD. This study supports the strong evidence for an association between obesity and CKD.

Keywords: Anthropometric measures, BMI, Chronic kidney disease, Obesity

Background

Worldwide, around 8–16 % of populations are suffering from chronic kidney disease (CKD) [1]. CKD is associated with a significantly higher risk of cardiovascular events, hospitalization and mortality, and the risk increases with the severity of CKD [1–4]. Many factors act synergistically in the development and progression of

*Correspondence: ensieh.memarian@med.lu.se
1 Department of Clinical Sciences in Malmö, Lund University, Internal Medicine – Epidemiology Research Group, Jan Waldenströms gata 15, 5th floor, Malmö, Sweden

Full list of author information is available at the end of the article
CKD, most importantly diabetes and hypertension [1]. Obesity, defined as a body mass index (BMI) $\geq 30 \text{kg/m}^2$, is associated with substantially increased incidence of type 2 diabetes and hypertension [5]. Notably, individuals with obesity who do not have metabolic abnormalities, also have a higher risk for CKD progression through other mechanisms than hypertension and diabetes [6].

BMI is the most practical and commonly used anthropometric measure for general adiposity [7–9]. However, BMI cannot differentiate between visceral fat and subcutaneous fat. Compared with subcutaneous fat, visceral fat has higher metabolic and inflammatory activity [10, 11]. Other anthropometric indicators that reflect obesity are waist circumference (WC), waist-to-hip ratio (WHR), percentage of body fat (BF%), and waist circumference to height ratio (WHR). According to a recent meta-analysis, WHtR could be a better predictor for CKD risk relative to other obesity measurements [12]. However, only one study (from Japan) had a prospective design and the authors concluded that high-quality prospective studies are needed to verify the usefulness of WHtR [12].

Another study from China indicated that BF% was a better measure to predict CKD development than other adiposity indices [13].

The aim of this large prospective study was to explore the association between several anthropometric measures of obesity, i.e., BMI, WC, WHtR, WHR, BF%, weight, height and incidence of hospitalizations due to CKD, in a population-based cohort study.

**Methods**

**Study population**

In the present study, we used the ‘Malmö Diet and Cancer Study (MDCS)’ cohort, from the city of Malmö in southern Sweden. Subjects in this study were men born between 1923 and 1945, and women born between 1923 and 1950, living in the city of Malmö, who were invited to participate in the MDCS baseline screening during 1991 to 1996, the participation rate was 41% [14, 15]. A total of 28,449 subjects underwent measurement of anthropometric measures and blood pressure and filled out a questionnaire. The anthropometric measures were obtained only once at the baseline screening during 1991 to 1996.

Subjects with a diagnosis of CKD at baseline were excluded (N=36). Subjects with missing values of anthropometric measurements and lifestyle, socioeconomic and other biological variables were also excluded (n=1688). Additionally, two subjects with mismatched BMI and waist circumference were excluded. The total population included in this study was 26,723 (10,264, 38.4% men, and 16,459, 61.6% women) individuals, aged 45–73 years.

**Baseline examinations**

The baseline examinations were performed by qualified nurses at the study center. Height in centimeter (cm) was measured in standing position with a fixed stadiometer. Weight was measured using balance-beam scale, to the nearest 0.1 kg, the subjects were wearing only light clothing and they were not wearing any shoes. BMI (kg/m$^2$) of the participants was calculated as weight (kg) divided by the square of the height (m$^2$). Participants’ WC (cm) was defined as the circumference between the lowest rib margin and iliac crest, and hip circumference was determined as the largest circumference between waist and thighs. The ratio of WC to hip circumference was considered WHR. The ratio of WC to height was defined as WHtR. These baseline examinations are performed for participants in MDCS cohort and have been mentioned in a study by Borné et al. [16].

Body composition, and BF% was calculated using Bioelectric Impedance Analyzers (BIA), based on the manufacturer instructions (BIA 103, RJL systems, single-frequency analyzer, Detroit, USA) [17]. All the anthropometric measures, i.e., weight, height, BMI, WC, WHR, WHtR and BF%, were categorized into quartiles Q1-Q4 for men and women.

Data on smoking, alcohol consumption, physical activity, educational level, marital status and immigrant status, as well as utilization of lipid-lowering, antihypertensive and diabetes medications, was collected through a questionnaire.

Blood pressure (mmHg) was checked by a nurse using a mercury-column sphygmomanometer after the subjects had rested for 10 minutes in a supine position. Diabetes mellitus was defined as self-reported physician’s diagnosis of diabetes or use of diabetes medications. Physical activity level was identified through 18 questions. The responses were weighted for the intensity of the various activities and added up to a physical activity score [18]. Low leisure-time physical activity was considered as the lowest third of the score.

Subjects’ smoking habits were categorized into two groups, non-smokers (ex-smokers and never-smokers) and smokers (occasional or habitual smokers). High alcohol consumption was considered as an alcohol consumption more than 30 grams per day for women and more than 40 g per day for men. Educational level was divided into three categories: less than 9 years (primary education), 9 - 12 years (some/completed secondary education), and more than 12 years (education at college or university level). Marital status was categorized into two groups; married/cohabitant and single (unmarried/widows/widowers). Country of births was classified as Swedish-born or foreign-born.
A subgroup of MDCS was randomly invited for a cardiovascular study [19]. In this subpopulation 4742 individuals had data available on estimated glomerular filtration rate (eGFR). Serum creatinine and cystatin C was measured in fasting blood samples that was collected at a second visit approximately four months after the first baseline examination. Blood samples were stored at -80 Celsius until analysis in 2012. Creatinine (μmol/L) was measured in plasma and analyzed with the Jaffé method and traceable to the international standardization with isotope dilution mass spectrometry (IDMS). Cystatin C was attained using a particle-enhanced immunonephelometric assay (N Latex Cystatin; Dade Behring, Deerfield, IL, USA). The values for cystatin C were analyzed before the introduction of the world calibrator in 2010 and thus not standardized. The reference value for the method was 0.53–0.95 mg/L. Calculation of eGFR was done according to the previously reported Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine–cystatin C equation [20]. A factor of 0.0113 was included to convert creatinine levels measured in μmol/l into mg/dl.

**Incidence of CKD**

The subjects included in this study were followed from the baseline examination in 1991-1996 until CKD diagnosis, death, emigration or end of study, December 31st, 2016, whichever came first.

Data on incident CKD was retrieved through linkage with the Swedish Cause of Death Register and the Swedish Patient Registers, which covers all inpatient diagnoses in Sweden since 1987 and all hospital outpatient diagnoses since 2001. The registers are managed by the Swedish National Board of Health and Welfare. In addition, the Swedish Kidney Quality Register 'Svenskt Njurregister' was used to identify severe CKD, in need of dialysis or transplantation [21].

Diagnoses were coded based on the International Classification of Disease (ICD). The 9th edition (ICD-9) was used during 1987 and 1996 and the 10th edition (ICD-10) from 1997 until present time. CKD was defined as codes 585–586 according to ICD-9, and N18 and N19 according to ICD-10.

A validation study has been performed to assess case validity of the CKD diagnosis from the Swedish patient registers [22]. In 100 randomly selected patients from MDCS, the CKD diagnoses were evaluated by two experienced specialists in nephrology using patient records and laboratory data. A CKD diagnosis requires two measuring points at least 3 months apart to meet the criteria [23]. The diagnoses were divided into four groups based on the degree of reliability: grade 0, incorrect diagnosis; grade 1, low probability of correct diagnosis, or insufficient information (e.g. eGFR 58 ml/min at one time only and no indication of albuminuria); grade 2, reasonable high probability of correct diagnosis (e.g. 2.5 months between creatinine analyzes instead of 3 months); grade 3, correct diagnosis. Grades 0–1 was considered incorrect. Grades 2–3 were considered to be correct. The final result showed 94 percent correct diagnoses, 5 incorrect diagnoses, and 1 case that cannot be classified as correct due to doubtful or insufficient data. Thus, the validation showed that 94% of the patients had a correct diagnosis of CKD.

**Statistical analysis**

Cox proportional hazards regression was used to examine the association between anthropometric measures such as BMI, WC, WHR, WHtR, BF%, weight and height (in sex-specific quartiles) and incidence of CKD. The time axis is follow-up time until emigration, incident CKD, death or end of follow-up. Hazard ratios (HR), with 95% confidence interval (CI) was calculated. A p-value < 0.05 was considered statistically significant.

Multivariable Cox proportional hazards models were adjusted as follows: In the basal model, HR were adjusted for age. In the second model, HR were adjusted for age and other biological risk factors such as systolic blood pressure, utilization of antihypertensive or lipid-lowering medications, diabetes mellitus, smoking habits, alcohol consumption and physical activity. In the third model, HR was further adjusted for age, biological risk factors and socioeconomic factors (i.e. marital status, immigration status and education) and eGFR.

In another analysis we categorized BMI and WC according to World Health Organization accepted risk-groups (WHO cut-offs).

BMI (kg/m²) was categorized for both sexes as followed:

1. BMI < 18.5 (underweight)
2. BMI 18.5-25 (normal)
3. BMI 25–29.99 (overweight)
4. BMI 30–35 (obese)
5. BMI > 35 (severely obese)

WC was categorized for men and women as followed:

1. WC < 94 for men and WC < 80 for women (normal)
2. WC 94-102 for men and WC 80-88 for women (overweight)
3. WC > 102 for men and WC > 88 for women (obese)

All analyses were performed using SPSS statistics program, version 25 (IBM, Armonk, NY, USA).

The study was conducted in full accordance with the World Medical Association Declaration of Helsinki.
Results

Study population
After exclusion of individuals with missing values and those with a prevalent CKD diagnosis at baseline, the final study population consisted of 26,723 subjects (10,264, 38.4% men, and 16,459, 61.6% women). The characteristics of the study population are presented in Table 1, for men and women separately. Except for BF%, mean values of all anthropometric measurements were higher among men compared to women. Moreover, men had higher proportions of hypertension, diabetes, smoking, high alcohol consumption, use of lipid lowering drugs, being married, low physical activity and low education compared to women.

The characteristics of the study participants who developed CKD (N=1012) compared to those who did not developed CKD (N=25,711) are also presented in Table 1. Men had higher incidence of CKD (N=590, 5.7%) compared to women (N=422, 2.6%). Except for BF%, the mean values of all anthropometric measurements were higher in subjects who developed CKD compared to those who did not. In addition, individuals with incident CKD had higher prevalence of hypertension, diabetes and lipid lowering drugs at baseline.

Risk of CKD in relation to anthropometric measures
Hazard ratios for CKD in relation to anthropometric measures in four quartiles (Q1-Q4) are presented in Table 1.

Table 1  Characteristics of cohort participants presenting men and women, incident CKD and healthy subjects separately

| Sex-specific characteristics | CKD during follow up | No CKD |
|-----------------------------|----------------------|-------|
|                             | Men (80%)            | Women (52.1%) | 1012 (3.3%) |
|                             | 10264 (38.4%)        | 16459 (61.6%) | 25711 |
| Incidence of CKD, n (per 1000 p-y) | 590 (3.3%) | 422 (1.4%) | 0 |
| Age at screening (years)    | 59 ± 7               | 57.8 ± 8     | 62 ± 7 |
| Height (cm)                | 176.5 ± 6.6          | 163.7 ± 6.1  | 170.3 ± 9.1 |
| Weight (kg)                | 81.7 ± 12.1          | 68.0 ± 11.6  | 79.5 ± 14.4 |
| BMI (kg/m2)                | 26.2 ± 3.5           | 25.4 ± 4.2   | 27.4 ± 4.5 |
| BF%                        | 20.7 ± 5.0           | 30.7 ± 5.0   | 26.4 ± 7.9 |
| WC (cm)                    | 93.5 ± 10.0          | 77.8 ± 10.5  | 91.3 ± 13.1 |
| WHR                        | 0.94 ± 0.06          | 0.79 ± 0.06  | 0.90 ± 0.09 |
| WHtR                       | 0.53 ± 0.06          | 0.48 ± 0.07  | 0.54 ± 0.07 |
| Systolic Blood Pressure (mmHg) | 144 ± 19            | 139 ± 20     | 153 ± 20 |
| Follow-up period (years)*  | 173 ± 5.0            | 182 ± 3.9    | 17.8 ± 3.6 |
| High Alcohol Consumption (> 40/30 gram per day for men/women), n (%) | 763 (7.4%) | 198 (2.4%) | 43 (4.2%) |
| Current smoking, n (%)     | 2952 (28.8%)         | 4592 (27.9%) | 286 (28.3%) |
| Current use of antihypertensive medicine, n (%) | 1859 (18.1%) | 2568 (15.6%) | 403 (39.8%) |
| Use of Lipid-lowering Drugs, n (%) | 348 (3.4%) | 297 (1.8%) | 62 (6.1%) |
| Diagnosed diabetes, n (%)  | 531 (5.2%)           | 506 (3.1%)   | 140 (13.8%) |
| Low physical activity, n (lowest quartile) (%) | 2603 (25.4%) | 4075 (24.8%) | 284 (28.1%) |
| Married, n (%)             | 7458 (72.7%)         | 10000 (60.8%) | 692 (68.4%) |
| Born in Sweden, n (%)      | 9033 (88.0%)         | 14519 (88.2%) | 906 (89.5%) |
| Immigrant to Sweden, n (%) | 1231 (12.0%)         | 1940 (11.8%) | 106 (10.5%) |
| Educational level          | 4646 (45.3%)         | 6423 (39.0%) | 532 (52.6%) |
| • Primary school education, n (%) | 2031 (19.8%) | 5022 (30.5%) | 236 (23.3%) |
| • Secondary school education, n (%) | 3587 (34.9%) | 5014 (30.5%) | 244 (24.1%) |

N=number
p-y = person years
CKD = Chronic kidney disease; BMI = body mass index; BF% = bodyfat-percentage; WHR = Waist-Hip Ratio; WC = Waist Circumference; WHtR = Waist-Height Ratio
Values are means ± standard deviation, unless stated otherwise
* Follow-up period from screening to emigration or death or last follow-up date (2013-12-31)
Tables 2 and 3 for men and women, respectively, and the corresponding Kaplan-Meier plots are presented in Supplementary Figures S2A-S2G and S3A-S3G. Higher values of BMI, WC, WHR, WHtR and weight were associated with an increased risk of developing CKD in both men and women in all three models. Only in women, higher values of BF% was associated with higher risk of CKD in all three models (Q4 vs. Q1 p-value <0.001). Height itself did not show any association with an increased risk of developing CKD in any of the sexes. The highest HRs for CKD in men (4th vs 1st quartile) was observed for BMI, HR 1.51 (95% CI: 1.18-1.94) and

Table 2 Hazard Ratios for incident CKD in relation to anthropometric measures in men

| Quartiles* | Q1    | Q2    | Q3    | Q4    | Q4 vs. Q1 p-value** |
|------------|-------|-------|-------|-------|---------------------|
| BMI (range, kg/m²) | < 23.9 | 23.9 - 26.0 | 26.0 - 28.1 | > 28.1 |                     |
| CKD¹       | 2.2   | 3.0   | 3.5   | 4.7   |                     |
| HR-1²      | 1     | 1.23 (0.95-1.60) | 1.42 (1.10-1.83) | 2.02 (1.58-2.57) | <0.001 |
| HR-2³      | 1     | 1.13 (0.87-1.47) | 1.28 (0.99-1.65) | 1.52 (1.18-1.95) | 0.001 |
| HR-3⁴      | 1     | 1.13 (0.87 -1.47) | 1.28 (0.99-1.66) | 1.51 (1.18-1.94) | 0.001 |
| WC (range, cm) | < 87  | 87-93  | 93-99  | >99   |                     |
| CKD¹       | 2.4   | 2.7   | 3.6   | 4.7   |                     |
| HR-1²      | 1     | 1.06 (0.82-1.38) | 1.39 (1.09-1.78) | 1.85 (1.46-2.35) | <0.001 |
| HR-2³      | 1     | 1.02 (0.79-1.33) | 1.24 (0.97-1.59) | 1.36 (1.06-1.74) | 0.014 |
| HR-3⁴      | 1     | 1.02 (0.79 -1.33) | 1.24 (0.97 -1.59) | 1.36 (1.06 -1.73) | 0.016 |
| WHR (range) | <0.90 | 0.90-0.94 | 0.94-0.98 | >0.98 |                     |
| CKD¹       | 2.6   | 3.2   | 3.4   | 4.2   |                     |
| HR-1²      | 1     | 1.26 (0.98-1.60) | 1.36 (1.07-1.73) | 1.88 (1.49-2.37) | <0.001 |
| HR-2³      | 1     | 1.16 (0.91-1.48) | 1.10 (0.86-1.40) | 1.38 (1.09-1.76) | 0.008 |
| HR-3⁴      | 1     | 1.15 (0.90 -1.47) | 1.09 (0.86 -1.39) | 1.36 (1.07 -1.74) | 0.012 |
| WHtR (range) | < 0.49 | 0.49-0.53 | 0.53-0.56 | >0.56 |                     |
| CKD¹       | 2.3   | 2.6   | 3.6   | 5.0   |                     |
| HR-1²      | 1     | 1.01 (0.78-1.32) | 1.38 (1.080-1.77) | 1.90 (1.51-2.41) | <0.001 |
| HR-2³      | 1     | 0.90 (0.69-1.18) | 1.19 (0.93-1.53) | 1.34 (1.05-1.70) | 0.020 |
| HR-3⁴      | 1     | 0.90 (0.69 -1.17) | 1.18 (0.92 -1.52) | 1.32 (1.03 -1.68) | 0.027 |
| BF% (range) | < 17.0 | 17.0-20.0 | 20.0-24.0 | > 24.0 |                     |
| CKD¹       | 3.2   | 2.7   | 3.2   | 4.3   |                     |
| HR-1²      | 1     | 0.85 (0.67-1.08) | 0.99 (0.78-1.25) | 1.37 (1.10-1.70) | 0.004 |
| HR-2³      | 1     | 0.77 (0.61-0.98) | 0.85 (0.67-1.07) | 1.08 (0.87-1.34) | 0.504 |
| HR-3⁴      | 1     | 0.77 (0.61 -0.98) | 0.84 (0.67 -1.07) | 1.07 (0.86 -1.34) | 0.537 |
| Weight (range, kg) | < 74.0 | 74.0-81.0 | 81.0-89.0 | > 89.0 |                     |
| CKD¹       | 2.5   | 3.2   | 3.5   | 4.2   |                     |
| HR-1²      | 1     | 1.21 (0.94-1.55) | 1.38 (1.08-1.76) | 1.84 (1.45-2.33) | <0.001 |
| HR-2³      | 1     | 1.17 (0.91-1.51) | 1.27(0.99-1.63) | 1.50 (1.18-1.91) | 0.001 |
| HR-3⁴      | 1     | 1.18 (0.92 -1.52) | 1.29 (1.00 -1.65) | 1.52 (1.19 -1.94) | 0.001 |
| Height (range, cm) | < 172.0 | 172.0-176.0 | 176.0-181.0 | > 181.0 |                     |
| CKD¹       | 3.7   | 4.0   | 2.9   | 2.9   |                     |
| HR-1²      | 1     | 1.15 (0.93-1.42) | 0.86 (0.68-1.09) | 0.98 (0.78-1.22) | 0.851 |
| HR-2³      | 1     | 1.17 (0.94-1.45) | 0.93 (0.73-1.18) | 1.06 (0.85-1.33) | 0.608 |
| HR-3⁴      | 1     | 1.17 (0.94 -1.46) | 0.95 (0.75 -1.20) | 1.09 (0.87 -1.38) | 0.450 |

*Each quartile includes approximately 2560 individuals. ** p-value < 0.05 is considered significant

1 CKD per 1000-person years; 2Cox-regression Hazard Ratio (HR) adjusted for age (95% CI); 3HR-2 adjusted for age, use of antihypertensive medication, lipid-lowering medication, systolic blood pressure, smoking, alcohol consumption, low physical activity and diabetes (95% CI); 4HR-3 adjusted for HR-2 plus low education, marital status and immigrant status (95% CI)

CKD Chronic kidney disease, BMI body mass index, WC waist circumference, WHR waist-hip ratio, WHtR waist-height ratio, BF% body-fat percentage, CI confidence interval
weight (HR 1.52 (95% CI: 1.19-1.94). For women the highest HR for CKD in 4th quartile was for BF%, HR 2.01 (95% CI: 1.45-2.78).

Graphic illustrations of hazard ratios for developing CKD for each anthropometric measure in men and women in four quartiles are presented in Fig. 1A and B. HRs are adjusted for age, use of antihypertensive and, lipid-lowering drugs, systolic blood pressure, smoking habits, low physical activity, diabetes, alcohol consumption, low education, marital status and immigrant status. As shown in the Fig. 1A and B, there is a significantly increased risk of developing CKD in the fourth (vs first) quartile for each anthropometric measure, except for height in both men and women.

Table 3  Hazard Ratios for incident CKD in relation to anthropometric measures in women

| Quartiles* | Q1 | Q2 | Q3 | Q4 | Q4 vs. Q1 p-value** |
|------------|----|----|----|----|---------------------|
| **BMI** (range, kg/m^2) | < 22.5 | 22.5-24.7 | 24.7-27.6 | > 27.6 |  |
| CKD^1 | 0.8 | 1.0 | 1.3 | 2.6 |  |
| HR-1^2 | 1 | 1.04 (0.74-1.45) | 1.23 (0.89-1.69) | 2.45 (1.83-3.26) | <0.001 |
| HR-2^3 | 1 | 0.99 (0.71-1.39) | 1.05 (0.76-1.45) | 1.65 (1.23-2.22) | <0.001 |
| HR-3^4 | 1 | 0.99 (0.71-1.39) | 1.05 (0.76-1.45) | 1.63 (1.21-2.20) | 0.011 |
| **WC** (range, cm) | < 70 | 70-76 | 76-83 | > 83 |  |
| CKD^1 | 0.8 | 0.8 | 1.2 | 2.9 |  |
| HR-1^2 | 1 | 0.87 (0.61-1.25) | 1.21 (0.89-1.66) | 2.68 (2.03-3.55) | <0.001 |
| HR-2^3 | 1 | 0.79 (0.55-1.14) | 1.06 (0.77-1.45) | 1.72 (1.29-2.30) | <0.001 |
| HR-3^4 | 1 | 0.79 (0.55-1.13) | 1.06 (0.77-1.45) | 1.70 (1.27-2.27) | 0.001 |
| **WHR** (range) | < 0.76 | 0.76-0.79 | 0.79-0.82 | > 0.82 |  |
| CKD^1 | 1.0 | 1.0 | 1.5 | 2.2 |  |
| HR-1^2 | 1 | 1.00 (0.73-1.37) | 1.43 (1.07-1.92) | 2.13 (1.63-2.79) | <0.001 |
| HR-2^3 | 1 | 0.93 (0.67-1.27) | 1.22 (0.91-1.64) | 1.42 (1.08-1.88) | 0.013 |
| HR-3^4 | 1 | 0.92 (0.67-1.27) | 1.21 (0.90-1.61) | 1.40 (1.06-1.85) | 0.018 |
| **WHtR** (range) | < 0.43 | 0.43-0.46 | 0.46-0.51 | > 0.51 |  |
| CKD^1 | 0.7 | 0.9 | 1.4 | 2.8 |  |
| HR-1^2 | 1 | 1.09 (0.75-1.56) | 1.57 (1.12-2.20) | 2.97 (2.18-4.05) | <0.001 |
| HR-2^3 | 1 | 0.98 (0.68-1.42) | 1.31 (0.93-1.84) | 1.85 (1.34-2.56) | <0.001 |
| HR-3^4 | 1 | 0.98 (0.68-1.41) | 1.30 (0.92-1.82) | 1.82 (1.32-2.52) | <0.001 |
| **BF%** (range) | < 27.0 | 27.0-31.0 | 31.0-34.0 | > 34 |  |
| CKD^1 | 0.7 | 0.9 | 1.3 | 2.8 |  |
| HR-1^2 | 1 | 1.21 (0.84-1.75) | 1.47 (1.06-2.04) | 2.98 (2.18-4.07) | <0.001 |
| HR-2^3 | 1 | 1.18 (0.81-1.70) | 1.25 (0.90-1.74) | 2.03 (1.48-2.81) | <0.001 |
| HR-3^4 | 1 | 1.18 (0.81-1.70) | 1.24 (0.89-1.73) | 2.01 (1.45-2.78) | <0.001 |
| **Weight** (range, kg) | < 60.0 | 60.0-66.0 | 66.0-74.0 | > 74.0 |  |
| CKD^1 | 1.0 | 0.9 | 1.4 | 2.4 |  |
| HR-1^2 | 1 | 0.89 (0.64-1.24) | 1.32 (0.98-1.76) | 2.31 (1.77-3.01) | <0.001 |
| HR-2^3 | 1 | 0.84 (0.61-1.17) | 1.17 (0.87-1.57) | 1.65 (1.25-2.16) | <0.001 |
| HR-3^4 | 1 | 0.84 (0.61-1.17) | 1.18 (0.88-1.58) | 1.64 (1.25-2.15) | <0.001 |
| **Height** (range, cm) | < 160.0 | 160.0-164.0 | 164.0-168.0 | > 168.0 |  |
| CKD^1 | 1.9 | 1.4 | 1.4 | 1.1 |  |
| HR-1^2 | 1 | 0.80 (0.62-1.04) | 0.90 (0.69-1.16) | 0.85 (0.65-1.12) | 0.252 |
| HR-2^3 | 1 | 0.84 (0.65-1.09) | 0.94 (0.72-1.22) | 0.94 (0.71-1.23) | 0.634 |
| HR-3^4 | 1 | 0.85 (0.66-1.11) | 0.96 (0.74-1.25) | 0.97 (0.73-1.28) | 0.807 |

*Each quartile includes approximately 4110 individuals. **p-value <0.05 is considered significant
1 CKD per 1000-person years; 2Cox-regression Hazard Ratio (HR) adjusted for age (95% CI); 3HR-2 adjusted for age, use of antihypertensive medication, lipid-lowering medication, systolic blood pressure, smoking, alcohol consumption, low physical activity and diabetes (95% CI); 4HR-3 adjusted for HR-2 plus low education, marital status and immigrant status (95% CI)

CKD Chronic kidney disease, BMI body mass index, WC waist circumference, WHR waist-hip ratio, WHtR waist-height ratio, BF % body-fat percentage, CI confidence interval

weight (HR 1.52 (95% CI: 1.19-1.94). For women the highest HR for CKD in 4th quartile was for BF%, HR 2.01 (95% CI: 1.45-2.78).
Supplementary Table S1 and Supplementary Figure S1A and S1B presents the hazard ratios for incidence of CKD in association to commonly used cut-offs for BMI and WC. As shown in this Table, high cut-off values for BMI and WC were associated with higher HRs for CKD.

Discussion

The results of this large prospective, population-based cohort study showed that higher values of anthropometric measures related to obesity such as BMI, WC, WHR, WHtR and weight in both sexes were major risk factors/markers for incident CKD, independently of several sociodemographic, lifestyle and biological factors. Body height was not associated with risk of CKD in neither men nor women and BF% did not show any association with risk of CKD in men.

Since obesity is an increasing health problem in most countries and a major risk factor for many diseases, it is important to identify and utilize the most informative measures of obesity for preventive purposes. Some observational studies have demonstrated that central obesity, such as WC or WHR, is associated with higher risk of CKD [24, 25], whereas other studies showed that anthropometric measures of general adiposity such as BMI and BF% provide a similar or better risk assessment [13, 26].

Although all obesity measures in our study were associated with higher risk of CKD, overall body weight in men, i.e. BMI and weight, tended to be more predictive for risk of CKD than measures of abdominal obesity, i.e. WC, WHR and WHtR. On the other hand, in women BF%, WHtR and WC were more predictive compared to BMI and weight.

Visceral fat is usually considered to be more metabolically active than subcutaneous fat, and thereby a better predictor of cardiometabolic risk [11]. It is therefore reasonable to believe that individuals with more visceral abdominal obesity could also run a higher risk of
developing CKD [27]. A recent study by Miyasato et al. suggested that visceral fat was the most sensitive obesity indicator for decline in kidney function [28]. However, a recent study showed that CT measures of obesity, such as visceral abdominal fat and subcutaneous adipose tissue, as well as BMI and WC were all significantly associated with kidney function decline, indicating that anthropometric measures of body fat such as BMI and WC appear to provide as consistent estimates of kidney function decline risk as CT measures [26]. Moreover, although advanced imaging technologies such as CT and MRI might provide a better evaluation of visceral adiposity, using them to screen for CKD risk in a large-scale population or in daily clinical practice is unrealistic due to high costs and high radiation exposure.

The incidence of CKD was higher for men compared to women. This might be explained by the fact that men had higher mean values of all anthropometric measurements (except for BF%) compared to women, as well as higher prevalence of hypertension, diabetes and some other risk factors. Our results also showed that some anthropometric measures of obesity were more predictive for men whereas others were more predictive for women, as mentioned above. A study from China showed that visceral adiposity index and lipid accumulation product index, which is based on a combination of WC and blood triglyceride, had higher predictive ability for identifying CKD in women, but not in men, as compared to traditional indices such as BMI [29]. The mechanisms causing gender-specific differences in CKD are not completely known. Sex hormones influence the fat distribution differently, which consequently might affect the association between obesity and CKD. This is supported by data from a study of male mice, which reported renoprotective effects after administration of estrogen [30]. According to a systematic review and meta-analysis by Wang et al., obesity increases the risk for developing CKD in the general population, however obesity in women was associated with higher risk of CKD compared to men [31]. A possible explanation might be that the differences in exposure to sex hormones in combination with obesity may cause the gender differences. Another explanation is that women in general have a higher percent body fat and more adipose tissue than men with the corresponding BMI [32]. Further studies are needed to clarify these differences.

Although many epidemiologic studies have shown that obesity and CKD are positively correlated, the mechanisms by which changes in adiposity affect CKD risk are not entirely clear. The Kaplan-Meier graphs for risk of CVD in relation to the quartiles of each anthropometric measure illustrated that the differences between quartiles first appear after 10 years of follow-up. Although the Cox models present the risk of CKD at any point in time during follow-up, the length of follow-up is essential for predicting the number of CKD outcomes. It is worth mentioning that earlier stages of CKD might be undetected or only diagnosed in primary health care, whereas only those with more advanced stages of CKD are hospitalized and thus included in this study.

Anthropometric variables are generally reliable measures, which can be measured with high precision and only change slowly over time. However, it is obvious that some individuals could have changed their weight and waist measures during the follow-up period. This would most likely dilute the relationships with incidence of CKD, if anything.

One question is whether bioelectrical impedance has similar validity and reliability. A validation study of the equipment used in the present study concluded that the validity and reliability was acceptable, and that the method could be of value both for clinical use and field studies [33]. However, others have questioned the precision of the bioelectrical impedance method, especially for individuals with body mass indices greater than 34 kg/m² [27]. These individuals often have a relatively high amount of extracellular water and total body water, which might result in an overestimation of fat-free mass and an underestimation of fat mass. Central body fat generally overestimates the percentage of fat-free mass and underestimates the percentage of fat mass in adults with overweight and obesity [34]. These limitations of the bioelectrical impedance method argue in favor of traditional anthropometric measurements for the assessment of obesity and risk of CKD.

**Strengths and limitations**

One of the important strengths of this study is the large population-based cohort and a long follow-up period with accumulation of many CKD events. All the subjects have been followed through the Swedish health care system, which has a complete documentation through national population-based registers. Another strength of this study is that a separate validation study has been performed to assess case validity of the CKD diagnosis from the Swedish patient registers, which showed that 94% of the patients had a correct diagnosis of CKD [22].

One potential study limitation might be that obese individuals, due to co-morbidities, seek medical care more often than non-obese individuals, resulting in more diagnosed cases of CKD in obese individuals. CKD might be undetected for a long time before the individual seeks medical care and cases that did not seek medical care might have been missed. However, this should be largely similar for different measures of obesity.
Another issue to be addressed is whether the study population was representative of the background population since the participation rate of MDCS was approximately 41% [14]. However, a previous health survey from the region, from the city of Malmö, with a 75% participation rate, showed no substantial difference in basic characteristics, such as smoking and obesity, between participants in the MDCS and the health survey [15].

The anthropometric measurements were performed once at the start of the follow up and we had no data about changes in obesity measures during the follow up period. However, anthropometric measures usually change slowly over time. Even though some individuals assuredly changed their weight and waist measures during the follow-up period, this would most likely dilute the relationships with incidence of CKD.

The results were adjusted for systolic blood pressure and anti-hypertensive medication at the baseline examination. It can similarly be assumed that blood pressure and treatment of hypertension often changed during the follow-up. This should also bias the results towards null, if anything. Another limitation is that no information about proteinuria was available. The study design was appropriate to evaluate incidence of hospitalizations due to CKD, but we could not evaluate the progression of impaired kidney function.

Further studies are warranted to investigate whether interventions to treat obesity, such as liraglutide or bariatric surgery, can also reduce risk of CKD.

Conclusion
In conclusion, in this large prospective study, all anthropometric measures of obesity were associated with a substantially increased incidence of CKD, except for BF% in men. Some measures were slightly more predictive for the risk of CKD than others such as BMI and weight in men and BF% in women. In clinical daily practice use of all anthropometric measures of obesity might be equally useful to assess the risk of developing CKD. This study supports the strong evidence for relation between obesity and CKD risk.

Abbreviations
BF%: Percentage of body fat; BIA: Bioelectric Impedance Analyzers; BMI: Body mass index; CI: Confidence interval; CKD: Chronic kidney disease; cm: centimeter; CT: Computerized tomography; eGFR: Estimated glomerular filtration rate; HR: Hazard Ratio; ICD: The International Classification of Disease; N: Number; MDCS: Malmö Diet and Cancer Study; WC: waist circumference; WHO: World Health Organization; WHR: Waist-to-hip ratio; WHtR: Waist circumference to height ratio.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12882-021-02531-7.

Additional file 1: Figure S1A: WHO BMI and WC cut-off specific hazard ratios in men. Figure S1B: WHO BMI and WC cut-off specific hazard ratios in women.

Additional file 2: Figure S2A-S2G: Survival analyses, men. Quartile specific (Q1-Q4) CKD-free survival rates for men for each anthropometric measure (2A BMI, 2B waist, 2C Waist-Hip Ratio (WHR), 2D Waist-Height Ratio (WHtR), 2E Bodyfat-% (BF%), 2F Weight and 2G Height. The y-axis describes the outcome (1 = 100 %) and the x-axis the follow-up period measured in years.

Additional file 3: Figures S3A-S3G: Survival analyses, women. Quartile specific (Q1-Q4) CKD-survival rates for men for each anthropometric measure (2A BMI, 2B waist, 2C Waist-Hip Ratio (WHR), 2D Waist-Height Ratio (WHtR), 2E Bodyfat-% (BF%), 2F Weight and 2G Height. The y-axis describes the outcome (1 = 100 %) and the x-axis the follow-up period measured in years.

Additional file 4: Table S1: WHO cut-offs’ specific Hazard Ratios for incidence of chronic kidney disease in men and women.

Acknowledgements
The Malmö diet and cancer study was financially supported by the Swedish Cancer Foundation, The Swedish Medical Research Council, The European Commission, the City of Malmo, the Swedish Dairy Association and the Albert Påhlsson Foundation.

Authors’ contributions
EM: Conception and design, analysis and interpretation of data, drafting of the manuscript, statistical analysis, final approval for the whole content. PN: Conception and design, critical revision of the manuscript for important intellectual content, final approval for the whole content. AC: Conception and design, critical revision of the manuscript for important intellectual content, final approval for the whole content. IZ: Conception and design, statistical analysis, final approval for the whole content. GE: Conception and design, analysis and interpretation of data, critical revision of the manuscript for important intellectual content, statistical analysis, supervision, final approval for the whole content. All the authors have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Funding
This study was supported by the Ernhold Lundström Foundation (EM) and Lund University Infrastructure grant “Malmö population-based cohorts” (STYR 2019/2046). The funders did not have any role in the design of the study, collection, analysis, and interpretation of data or in writing the manuscript. Open access funding provided by Lund University.

Availability of data and materials
The datasets used and analysed during the current study are available after application to the MDCS steering committee on reasonable request. Email: Anders.Dahlin@med.lu.se.

Declarations
Ethics approval and consent to participate
This study has been approved by Ethical committee, University of Lund. Ethical approval number LU 51/90; LU 166/2007; LU 2016/387.

Informed consent was obtained from all subjects.

Consent for publication
Not applicable
Competing interests
The Authors declare that they have no competing interest.

Author details
1 Department of Clinical Sciences in Malmö, Lund University, Internal Medicine – Epidemiology Research Group, Jan Waldenström gata 15, 5th floor, Malmö, Sweden. 2 Department of Nephrology, Skåne University Hospital, Lund University, S-20502 Malmo, Sweden.

Received: 23 April 2021 Accepted: 9 September 2021 Published online: 05 October 2021

References
1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72.
2. Herzog CA, Asinger RW, Berger AK, Charytan DM, Dzie J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(6):572–86.
3. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population-based cohort study. BMJ. 2010;341:c4986.
4. Go AS, Chertow GM, Fan D, McCulough CE, Harn C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.
5. Borné Y, Nilsson PM, Melander O, Hedblad B, Engström G. Multiple anthropometric measures in relation to incidence of diabetes. a Swedish population-based cohort study. Eur J Pub Health. 2015;25(6):1100–5.
6. Yun HR, Kim H, Park J, Chang T, Yoo TH, Kang SW, et al. Obesity, Metabolic Abnormality, and Progression of CKD. Am J Kidney Dis. 2018;72(3):400–10.
7. Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007;30(6):1562–6.
8. Taylor AE, Ebrahim S, Ben-Shlomo Y, Martin RM, Whincup PH, Yarnell JW, et al. Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. Am J Clin Nutr. 2010;91(3):547–56.
9. Arnlöv J, Sundström J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. Diabetes Care. 2011;34(1):61–5.
10. Kosacka J, Kern M, Klötting N, Paescheck S, Rudich A, Hain Y, et al. Autophagy in adipose tissue of patients with obesity and type 2 diabetes. Mol Cell Endocrinol. 2013;409:21–32.
11. Koster A, Stenholm S, Alley DE, Kim LJ, Simonsick EM, Kanaya AM, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome: Obesity (Silver Spring). 2010;18(12):2354–61.
12. Liu L, Wang Y, Zhang W, Chang W, Jin Y, Yao Y. Waist height ratio predicts chronic kidney disease: a systematic review and meta-analysis, 1998–2019. Arch Public Health. 2019;77:55.
13. Dong Y, Wang Z, Chen Z, Wang X, Zhang L, Nie J, et al. Comparison of visceral, body fat indices and anthropometric measures in relation to chronic kidney disease among Chinese adults: from a large scale cross-sectional study. BMC Nephrol. 2018;19(1):40.
14. Berglund G, Elmstähl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med. 1993;233(1):45–51.
15. Manger J, Carlsson S, Elmstahl S, et al. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev. 2001;10(6):489–99.
16. Borné Y, Hedblad B, Essén B, Engström G. Anthropometric measures in relation to risk of heart failure hospitalization: a Swedish population-based cohort study. Eur J Pub Health. 2014;24(2):215–20.
17. Lahmann PH, Lissner L, Gullberg B, Berglund G. Differences in body fat and central adiposity between Swedes and European immigrants: the Malmö Diet and Cancer Study. Obes Res. 2000;8(10):620–31.
18. Mutie PM, Drake L, Ericson U, Teleka S, Schulz CA, Stocks T, et al. Different domains of self-reported physical activity and risk of type 2 diabetes in a population-based Swedish cohort: the Malmö diet and Cancer study. BMC Public Health. 2020;20(1):261.
19. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. Diabet Med. 2000;17(4):299–307.
20. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–9.
21. Landberg R, Berg D, Lindblad P, Ljungberg B, Lundstam S, Thorstenson A, et al. Validation of data quality in the National Swedish Kidney Cancer Register. Scand J Urol. 2021;55(2):142–8. https://doi.org/10.1080/21681 819.2021.1985485. Epub 2021 Feb 18. PMID: 33590561.
22. Harari F, Sallsten G, Christenson A, Petkovic M, Hedblad B, Forsgard N, et al. Blood Lead Levels and Decreased Kidney Function in a Population-Based Cohort. Am J Kidney Dis. 2018;72(3):381–9.
23. Stevens PE, Levin A, Members KGDNCKGDWDG. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Am Intern Med. 2013;158(11):825–30.
24. Elsayed EF, Sarnak MJ, Tighiouart H, Griffith JL, Kurth T, Salem DN, et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis. 2008;52(1):29–38.
25. Noon N, Hosseiniyan F, Nasir AA, Aziz F. Comparison of overall obesity and abdominal adiposity in predicting chronic kidney disease incidence among adults. J Ren Nutr. 2009;19(3):228–37.
26. Madore M, Katz R, Murphy R, Newman A, Patel K, Ix J, et al. Comparison between Different Measures of Body Fat with Kidney Function Decline and Incident CKD. Clin Am Soc Nephrol. 2017;12(6):893–903.
27. Xiao H, Xiong C, Shao X, Gao P, Chen H, Ning J, et al. Visceral Adiposity Index and Chronic Kidney Disease in a Non-Diabetic Population: A Cross-Sectional Study. Diabetes Metab Syndr Obes. 2020;13:257–65.
28. Miyasato Y, Obka Y, Yamasaki M, Sugiyama S, Fumii A, Takada S, et al. Associations between visceral obesity and renal impairment in health checkup participants: a retrospective cohort study. Clin Exp Nephrol. 2020;24(10):935–45.
29. Dai D, Chang Y, Chen Y, Chen S, Yu S, Guo X, et al. Visceral Adiposity Index and Lipid Accumulation Product Index: Two Alternate Body Indices to Identify Chronic Kidney Disease among the Rural Population in Northeast China. Int J Environ Res Public Health. 2016;13(12):1231. https://doi.org/ 10.3390/ijerph13121231. PMID: 27838609; PMCID: PMC5201372.
30. Ikeda M, Swide T, Vayl A, Lahm T, Anderson S, Huchten MP. Estrogen administered after cardiac arrest and cardiopulmonary resuscitation ameliorates acute kidney injury in a sex- and age-specific manner. Crit Care. 2015;19:332.
31. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73(1):19–33.
32. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293(4):455–62.
33. Steen B, Bosaues I, Elmstahl S, Galvand H, Isaksson B, Robertson S. Body composition in the elderly estimated with an electrical impedance method. Compr Gerontol A. 1987;13:102–5.
34. Coppini LZ, Watzberg DL, Campos AC. Limitations and validation of bioelectrical impedance analysis in morbidly obese patients. Curr Opin Clin Nutr Metab Care. 2005;8(3):329–32.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.